Article thumbnail
Location of Repository

Biphosphonates-related osteonecrosis of the jaw: Clinical and physiopathological considerations

By Alberto Borgioli, Christian Viviani, Marco Duvina, Leila Brancato, Giuseppe Spinelli, Maria Luisa Brandi and Paolo Tonelli

Abstract

Since osteonecrosis of the jaw was related to biphosphonate administration by Marx, studies showing clinical symptoms, drug and surgical therapies overwhelmed the literature. Furthermore, the literature demonstrated the correlation between chronic biphosphonate adsumption and osteonecrosis of the jaw onset. Nitrogen-containing biphosphonates are widely used for the management of metastatic cancer, for prevention and treatment of osteoporosis, for the treatment of Paget's disease, and for the management of acute hypercalcemia. According to our experience, the treatment of BRON-J's lesions is difficult and prolonged. For this reason, in order to avoid these complications it is mandatory to perform a risk staging in patients who must undergo biphosphonate administration. When pharmacologic treatments with antibiotics and local antiseptics are not able to control the development of BRON-J's complications, the clinicians should perform radical surgical treatments such as the resection of the bone involved

Topics: Original Research
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:2697532
Provided by: PubMed Central

Suggested articles

Citations

  1. (2006). American Association of Oral and Maxillofacial Surgeons. Position paper on bisphosphonate-related osteonecrosis of the jaws, approved by the Board of Trustees
  2. American Society of Clinical Oncology Bisphosphonates Expert Panel. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma.
  3. (2005). Bisphosphonatesinduced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention and treatment. J Oral Maxillofac Surg.
  4. (2006). Breast cancer: bisphosphonates therapy for metastatic bone disease. Clin Cancer Res.
  5. (2006). Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper. J Am Dent Assoc. 2005;136:1658–1668. Erratum in: J Am Dent Assoc.
  6. (2003). Multiple event analysis of zoledronic acid trials in patients with cancer metastases to bone. Proc Am Soc Clin Oncol.
  7. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors.
  8. Osteonecrosis of the jaw in newly diagnosed multiple myeloma patient treated with zoledronic acid and thalidomidedexamethasone.
  9. Osteonecrosis of the jaw in patient with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid.
  10. Osteonecrosis of the jaws associated with the use of bisphophonates; a review of 63 cases.
  11. (2003). Pamidronate (Aredia) and zoledonate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg.
  12. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one ostelytic lesion.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.